Important Information for Investors: Pacira BioSciences, Inc. Securities Class Action Lawsuit
Investors who purchased the securities of Pacira BioSciences, Inc. (PCRX) between August 2, 2023, and August 8, 2024, are encouraged to contact Kahn Swick & Foti, LLC (KSF) and former Attorney General of Louisiana, Charles C. Foti, Jr., regarding a potential securities class action lawsuit. The deadline to file for lead plaintiff applications is fast approaching, with a final deadline of March 14, 2025.
Background on the Class Action Lawsuit
KSF and Foti filed the lawsuit against Pacira BioSciences, Inc. on behalf of all persons or entities who purchased or otherwise acquired securities of the Company during the Class Period. The complaint alleges that the Company and certain of its executives and directors made false and/or misleading statements and/or failed to disclose material information regarding the Company’s business, operations, and financial condition.
Alleged Misstatements and Failures to Disclose
According to the complaint, the Company and its executives made false and/or misleading statements and/or failed to disclose that:
- The Company’s EXPAREL product was facing increased competition from generic versions and biosimilar products;
- The Company’s sales and marketing efforts for EXPAREL were not generating the expected results;
- The Company’s financial results would be negatively impacted;
- The Company’s financial statements were not accurately reflecting the true financial condition of the Company.
Impact on Individual Investors
If you purchased Pacira BioSciences securities during the Class Period and have suffered a loss, you may be eligible to recover your losses. KSF encourages investors to contact the Firm as soon as possible to discuss their legal rights and potential remedies. You can contact KSF by calling toll-free at 1-877-515-1850 or emailing [email protected] to speak with a securities attorney.
Impact on the World
The securities class action lawsuit against Pacira BioSciences, Inc. is significant because it highlights the importance of accurate and transparent disclosures by publicly traded companies. Misrepresentations and failures to disclose material information can have a negative impact on investors, as well as the broader financial markets. The lawsuit also underscores the role that securities class action lawsuits play in holding companies and their executives accountable for their actions.
Conclusion
If you purchased Pacira BioSciences securities during the Class Period and have suffered a loss, you may be eligible to recover your losses. KSF encourages investors to contact the Firm as soon as possible to discuss their legal rights and potential remedies. The deadline to file for lead plaintiff applications is March 14, 2025. For more information, you can visit KSF’s website at https://www.ksfcounsel.com/cases/nasdaqgs-pcrx/ or call toll-free at 1-877-515-1850.
The securities class action lawsuit against Pacira BioSciences, Inc. is a reminder of the importance of accurate and transparent disclosures by publicly traded companies. Misrepresentations and failures to disclose material information can have a negative impact on investors and the broader financial markets. KSF will continue to monitor this situation closely and provide updates as new information becomes available.
